{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:13:21Z","timestamp":1794456801529,"version":"4.9.1"},"reference-count":50,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0143","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T13:22:48Z","timestamp":1622467368000},"source":"Crossref","is-referenced-by-count":11,"title":["The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors"],"prefix":"10.3238","author":[{"given":"Knut","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen B.","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"10.3238\/arztebl.m2021.0143_ref1","doi-asserted-by":"crossref","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK, et al.: A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 2019; 145: 639\u201348","DOI":"10.1002\/ijc.32132"},{"key":"10.3238\/arztebl.m2021.0143_ref2","doi-asserted-by":"crossref","unstructured":"Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L: Checkpoint inhibitors. Dtsch Arztebl Int 2019; 116: 119\u201326","DOI":"10.3238\/arztebl.2019.0119"},{"key":"10.3238\/arztebl.m2021.0143_ref3","doi-asserted-by":"crossref","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B: A systematic review and meta-analysis of endocrine-related adverse events associated with immune Checkpoint Inhibitors. Horm Metab Res 2019; 51: 145\u201356","DOI":"10.1055\/a-0843-3366"},{"key":"10.3238\/arztebl.m2021.0143_ref4","doi-asserted-by":"crossref","unstructured":"Clotman K, Janssens K, Specenier P, Weets I, De Block CEM: Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 2018; 103: 3144\u201354","DOI":"10.1210\/jc.2018-00728"},{"key":"10.3238\/arztebl.m2021.0143_ref5","doi-asserted-by":"crossref","unstructured":"Bai X, Lin X, Zheng K, et al.: Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine 2020; 69: 670\u201381","DOI":"10.1007\/s12020-020-02355-9"},{"key":"10.3238\/arztebl.m2021.0143_ref6","doi-asserted-by":"crossref","unstructured":"Haanen J, Carbonnel F, Robert C, et al.: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv264\u2013iv6","DOI":"10.1093\/annonc\/mdy162"},{"key":"10.3238\/arztebl.m2021.0143_ref7","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714\u201368","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"10.3238\/arztebl.m2021.0143_ref8","doi-asserted-by":"crossref","unstructured":"Higham CE, Olsson-Brown A, Carroll P, et al.: Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 2018; 7: G1\u2013G7","DOI":"10.1530\/EC-18-0068"},{"key":"10.3238\/arztebl.m2021.0143_ref9","doi-asserted-by":"crossref","unstructured":"Castinetti F, Albarel F, Archambeaud F, et al.: French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 2019; 26: G1\u2013G18","DOI":"10.1530\/ERC-18-0320"},{"key":"10.3238\/arztebl.m2021.0143_ref10","doi-asserted-by":"crossref","unstructured":"Agrawal L, Bacal A, Jain S, et al.: Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgraduate Medicine 2020; 132: 206\u201314","DOI":"10.1080\/00325481.2019.1709344"},{"key":"10.3238\/arztebl.m2021.0143_ref11","doi-asserted-by":"crossref","unstructured":"Faje A, Reynolds K, Zubiri L, et al.: Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 2019; 181: 211\u20139","DOI":"10.1530\/EJE-19-0238"},{"key":"10.3238\/arztebl.m2021.0143_ref12","doi-asserted-by":"crossref","unstructured":"Faje AT, Sullivan R, Lawrence D, et al.: Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99: 4078\u201385","DOI":"10.1210\/jc.2014-2306"},{"key":"10.3238\/arztebl.m2021.0143_ref13","doi-asserted-by":"crossref","unstructured":"Albarel F, Castinetti F, Brue T: Management of endocrine disease: immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 2019; 181: R107\u2013R18","DOI":"10.1530\/EJE-19-0169"},{"key":"10.3238\/arztebl.m2021.0143_ref14","doi-asserted-by":"crossref","unstructured":"Lebbe C, Meyer N, Mortier L, et al.: Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the Phase IIIb\/IV CheckMate 511 Trial. J Clin Oncol 2019; 37: 867\u201375","DOI":"10.1200\/JCO.18.01998"},{"key":"10.3238\/arztebl.m2021.0143_ref15","doi-asserted-by":"crossref","unstructured":"Yang JC, Hughes M, Kammula U, et al.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825\u201330","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"10.3238\/arztebl.m2021.0143_ref16","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Del Vecchio M, Mackiewicz A, et al.: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg\/kg with 3 mg\/kg in patients with advanced melanoma. J Immunother Cancer 2020; 8: 1\u20137","DOI":"10.1136\/jitc-2019-000391"},{"key":"10.3238\/arztebl.m2021.0143_ref17","doi-asserted-by":"crossref","unstructured":"Albarel F, Gaudy C, Castinetti F, et al.: Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015; 172: 195\u2013204","DOI":"10.1530\/EJE-14-0845"},{"key":"10.3238\/arztebl.m2021.0143_ref18","doi-asserted-by":"crossref","unstructured":"Honegger J, Schlaffer S, Menzel C, et al.: Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab 2015; 100: 3841\u20139","DOI":"10.1210\/jc.2015-2152"},{"key":"10.3238\/arztebl.m2021.0143_ref19","doi-asserted-by":"crossref","unstructured":"Yuen KCJ, Popovic V, Trainer PJ: New causes of hypophysitis. Best Pract Res Clin Endocrinol Metab 2019; 33: 101276","DOI":"10.1016\/j.beem.2019.04.010"},{"key":"10.3238\/arztebl.m2021.0143_ref20","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L: Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 2018; 124: 1111\u201321","DOI":"10.1002\/cncr.31200"},{"key":"10.3238\/arztebl.m2021.0143_ref21","doi-asserted-by":"crossref","unstructured":"Arlt W, and the Society for Endocrinology Clinical Committee: Society for endocrinology endocrine emergency guidance: emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect 2016; 5: G1\u2013G3","DOI":"10.1530\/EC-16-0054"},{"key":"10.3238\/arztebl.m2021.0143_ref22","doi-asserted-by":"crossref","unstructured":"Bornstein SR, Allolio B, Arlt W, et al.: Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 364\u201389","DOI":"10.1210\/jc.2015-1710"},{"key":"10.3238\/arztebl.m2021.0143_ref23","doi-asserted-by":"crossref","unstructured":"Burger-Stritt S, Eff A, Quinkler M, et al.: Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. Eur J Endocrinol 2020; 183: 119\u201327","DOI":"10.1530\/EJE-20-0181"},{"key":"10.3238\/arztebl.m2021.0143_ref24","doi-asserted-by":"crossref","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, et al.: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015; 21: 749\u201355","DOI":"10.1158\/1078-0432.CCR-14-2353"},{"key":"10.3238\/arztebl.m2021.0143_ref25","doi-asserted-by":"crossref","unstructured":"Faje AT, Lawrence D, Flaherty K, et al.: High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 2018; 124: 3706\u201314","DOI":"10.1002\/cncr.31629"},{"key":"10.3238\/arztebl.m2021.0143_ref26","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 173\u201382","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"10.3238\/arztebl.m2021.0143_ref27","doi-asserted-by":"crossref","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L: Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 2019; 40: 17\u201365","DOI":"10.1210\/er.2018-00006"},{"key":"10.3238\/arztebl.m2021.0143_ref28","doi-asserted-by":"crossref","unstructured":"Ma C, Hodi FS, Giobbie-Hurder A, et al.: The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders. Cancer Immunol Res 2019; 7: 1214\u201320","DOI":"10.1158\/2326-6066.CIR-18-0613"},{"key":"10.3238\/arztebl.m2021.0143_ref29","doi-asserted-by":"crossref","unstructured":"Yamauchi I, Sakane Y, Fukuda Y, et al.: Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 2017; 27: 894\u2013901","DOI":"10.1089\/thy.2016.0562"},{"key":"10.3238\/arztebl.m2021.0143_ref30","doi-asserted-by":"crossref","unstructured":"Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL: Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management. Oncologist 2019; 25: 290\u2013300","DOI":"10.1634\/theoncologist.2018-0470"},{"key":"10.3238\/arztebl.m2021.0143_ref31","doi-asserted-by":"crossref","unstructured":"Quandt Z, Young A, Anderson M: Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 2020; 200: 131\u201340","DOI":"10.1111\/cei.13424"},{"key":"10.3238\/arztebl.m2021.0143_ref32","doi-asserted-by":"crossref","unstructured":"Barnabei A, Carpano S, Chiefari A, et al.: Case report: ipilimumab-induced panhypophysitis: an infrequent occurrence and literature review. Front Oncol 2020; 10: 582394","DOI":"10.3389\/fonc.2020.582394"},{"key":"10.3238\/arztebl.m2021.0143_ref33","doi-asserted-by":"crossref","unstructured":"Edahiro R, Ishijima M, Kurebe H, et al.: Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report. Thorac Cancer 2019; 10: 1276\u20139","DOI":"10.1111\/1759-7714.13065"},{"key":"10.3238\/arztebl.m2021.0143_ref34","doi-asserted-by":"crossref","unstructured":"Hofmann L, Forschner A, Loquai C, et al.: Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190\u2013209","DOI":"10.1016\/j.ejca.2016.02.025"},{"key":"10.3238\/arztebl.m2021.0143_ref35","doi-asserted-by":"crossref","unstructured":"Faje A: Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19: 82\u201392","DOI":"10.1007\/s11102-015-0671-4"},{"key":"10.3238\/arztebl.m2021.0143_ref36","doi-asserted-by":"crossref","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M: Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017; 13: 195\u2013207","DOI":"10.1038\/nrendo.2016.205"},{"key":"10.3238\/arztebl.m2021.0143_ref37","doi-asserted-by":"crossref","unstructured":"Stelmachowska-Banas M, Czajka-Oraniec I: Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 2020; 9: R207\u2013R28","DOI":"10.1530\/EC-20-0342"},{"key":"10.3238\/arztebl.m2021.0143_ref38","doi-asserted-by":"crossref","unstructured":"Deligiorgi MV, Panayiotidis MI, Trafalis DT: Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy 2020; 12: 481\u2013510","DOI":"10.2217\/imt-2019-0132"},{"key":"10.3238\/arztebl.m2021.0143_ref39","doi-asserted-by":"crossref","unstructured":"Prete A, Taylor AE, Bancos I, et al.: Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery. J Clin Endocrinol Metab 2020; 105: 2262\u201374","DOI":"10.1210\/clinem\/dgaa133"},{"key":"10.3238\/arztebl.m2021.0143_ref40","doi-asserted-by":"crossref","unstructured":"Tsoli M, Kaltsas G, Angelousi A, Alexandraki K, Randeva H, Kassi E: Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies. Cancer Manag Res 2020; 12: 9551\u201361","DOI":"10.2147\/CMAR.S224791"},{"key":"10.3238\/arztebl.m2021.0143_ref41","doi-asserted-by":"crossref","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139\u201348","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"10.3238\/arztebl.m2021.0143_ref42","doi-asserted-by":"crossref","unstructured":"Zhao C, Tella SH, Del Rivero J, et al.: Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab 2018; 103: 365\u20139","DOI":"10.1210\/jc.2017-01905"},{"key":"10.3238\/arztebl.m2021.0143_ref43","doi-asserted-by":"crossref","unstructured":"Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab 2019; 104: 550\u20136","DOI":"10.1210\/jc.2018-01151"},{"key":"10.3238\/arztebl.m2021.0143_ref44","doi-asserted-by":"crossref","unstructured":"Couey MA, Bell RB, Patel AA, et al.: Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 2019; 7: 165","DOI":"10.1186\/s40425-019-0645-6"},{"key":"10.3238\/arztebl.m2021.0143_ref45","doi-asserted-by":"crossref","unstructured":"Quinkler M, Beuschlein F, Hahner S, Meyer G, Schofl C, Stalla GK: Adrenal cortical insufficiency--a life threatening illness with multiple etiologies. Dtsch Arztebl Int 2013; 110: 882\u20138","DOI":"10.3238\/arztebl.2013.0882"},{"key":"10.3238\/arztebl.m2021.0143_ref46","unstructured":"Netzwerk f\u00fcr Hypophysen- und Nebennierenerkrankungen e. V.: Notfall-Ausweis. https:\/\/www.endokrinologie.net\/files\/download\/glukokortikoide-notfallausweis.pdf (last accessed on 14 May 2021)."},{"key":"10.3238\/arztebl.m2021.0143_ref47","doi-asserted-by":"crossref","unstructured":"Borodic G, Hinkle DM, Cia Y: Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 2011; 27: e87\u20138","DOI":"10.1097\/IOP.0b013e3181ef72a1"},{"key":"10.3238\/arztebl.m2021.0143_ref48","doi-asserted-by":"crossref","unstructured":"Paepegaey AC, Lheure C, Ratour C, et al.: Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc 2017; 1: 646\u20139","DOI":"10.1210\/js.2017-00170"},{"key":"10.3238\/arztebl.m2021.0143_ref49","unstructured":"Paul-Ehrlich-Institut: Schulungsmaterial. https:\/\/www.pei.de\/DE\/arzneimittelsicherheit\/schulungsmaterial\/schulungsmaterial-node.html (last accessed on 14 May 2021)."},{"key":"10.3238\/arztebl.m2021.0143_ref50","doi-asserted-by":"crossref","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21: 371\u201381","DOI":"10.1530\/ERC-13-0499"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:50:36Z","timestamp":1638784236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":50,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0143","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}